FY2026 Earnings Forecast for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA) – Investment analysts at HC Wainwright cut their FY2026 earnings estimates for shares of Savara in a research report issued on Monday, March 16th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.49) per share for the year, down from their prior forecast of ($0.39). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s FY2027 earnings at ($0.28) EPS and FY2028 earnings at $0.02 EPS.

Several other equities research analysts also recently issued reports on the company. UBS Group set a $10.00 price objective on Savara in a report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. Wells Fargo & Company lifted their price target on shares of Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, December 18th. Guggenheim reiterated a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. Finally, William Blair set a $10.00 target price on shares of Savara in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Savara Trading Down 1.5%

Shares of SVRA opened at $5.15 on Wednesday. Savara has a one year low of $1.89 and a one year high of $7.01. The stock has a 50-day moving average price of $5.65 and a 200 day moving average price of $4.99. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.65 and a current ratio of 11.85. The company has a market capitalization of $1.05 billion, a P/E ratio of -9.72 and a beta of 0.31.

Savara (NASDAQ:SVRA) last announced its earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Institutional Investors Weigh In On Savara

Hedge funds have recently added to or reduced their stakes in the stock. Prudential Financial Inc. acquired a new stake in shares of Savara in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets grew its position in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP acquired a new stake in shares of Savara in the second quarter valued at approximately $33,000. Russell Investments Group Ltd. raised its holdings in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of Savara during the second quarter valued at approximately $42,000. 87.93% of the stock is currently owned by institutional investors.

Trending Headlines about Savara

Here are the key news stories impacting Savara this week:

• Positive Sentiment: Lifesci Capital raised its Q2 2026 EPS forecast slightly (from ($0.13) to ($0.12)) and trimmed FY2026 loss expectations marginally (to ($0.48) from ($0.49)), signaling a small improvement in near-term outlook. MarketBeat SVRA
• Positive Sentiment: HC Wainwright maintained a “Buy” rating on SVRA, which supports investor demand and suggests confidence in Savara’s longer-term commercial potential despite model changes. MarketBeat SVRA
• Neutral Sentiment: HC Wainwright published detailed quarterly cadence estimates for 2026 (Q1–Q4) and multi-year projections that give investors updated milestones to watch, but these are expectations rather than new company results. MarketBeat SVRA
• Negative Sentiment: HC Wainwright cut FY2026 EPS to ($0.49) from ($0.39), increasing the near-term loss outlook and likely weighing on the stock as investors reassess cash runway and commercialization timing. MarketBeat SVRA
• Negative Sentiment: HC Wainwright lowered FY2027 and FY2028 forecasts (FY2027 to ($0.28) from ($0.16); FY2028 to $0.02 from $0.13), and also trimmed FY2029/FY2030 upside — these pushes out and reduce expected profitability, pressuring valuation that had factored in stronger long-term growth. MarketBeat SVRA

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.